Hong Kong homeopathy company Living Homeopathy International (LHI.US) withdraws $19 million US IPO plan
According to information from Zhihui Finance APP, Hong Kong healthcare service provider Living Homeopathy International (LHI.US) withdrew its initial public offering (IPO) plan on Tuesday, August 18. The company originally submitted a listing application in May 2025 and revised its offering terms in March 2026, intending to issue 3.8 million shares at a price range of $4 to $6 per share, aiming to raise approximately $19 million.
Living Homeopathy International provides healthcare products, including homeopathy products (accounting for 9% of revenue in fiscal year 2024), homeopathic adjunct therapy products (80%), and flower remedy products (4%). These products are mainly sourced from manufacturers and resold under the LIVING brand. In addition, the company develops and collaborates with manufacturers to produce personal care products (2%; such as mouthwash, toothpaste, shampoo) and water filtration products (4%).
According to Frost & Sullivan data, measured by sales revenue of homeopathy products in Hong Kong in 2023, Living Homeopathy International ranked first among all homeopathy service providers in Hong Kong, with a market share of about 41.3%.
The company was established in 1994 and originally planned to list on Nasdaq under the stock code “LHI”. Revere Securities was set to be the sole bookrunner for this offering.
